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Abstract
The clear association of Th17 cells with autoimmune pathogenicity implicates Th17 cytokines as critical
mediators of chronic autoimmune diseases such as EAE. To study the impact of IL-17A on CNS
inflammation, we generated transgenic mice in which high levels of expression of IL-17A could be
initiated after Cre-mediated recombination. Although ubiquitous overexpression of IL-17A led to skin
inflammation and granulocytosis, T cell-specific IL-17A overexpression did not have a perceptible
impact on the development and health of the mice. In the context of EAE, neither the T cell-driven
overexpression of IL-17A nor its complete loss had a major impact on the development of clinical
disease. Since IL-17F may be able to compensate for the loss of IL-17A, we also generated
IL-17F-deficient mice. This strain was fully susceptible to EAE and displayed unaltered emergence and
expansion of autoreactive T cells during disease. To eliminate potential compensatory effects of either
cytokine, we treated IL-17F-deficient mice with antagonistic monoclonal antibodies specific for IL-17A
and found again only a minimal beneficial impact on disease development. We conclude therefore that
both IL-17A and IL-17F, while prominently expressed by an encephalitogenic T cell population, may
only marginally contribute to the development of autoimmune CNS disease.
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IL-17A–overexpressing T cells do not enhance the pathogenesis and clini-
cal development of myelin oligodendrocyte glycoprotein–induced EAE. 
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Figure 
IL-17A overexpression does not exacerbate EAE. (A) LNs from CD4-IL17Aind/+ and IL-17Aind/+ littermates were isolated and stained for CD4 and 
CD8 coreceptors. EGFP expression is depicted in the histograms after indicated gating. Percentages of gated cells are shown. (B) Splenocytes 
from naive CD4-IL17Aind/+ mice were restimulated in the presence of Brefeldin A and subsequently stained for CD4 and IL-17A. Percentages 
of cells in the quadrants are indicated in the corners after gating was performed on all EGFP– (plots on the left) or all EGFP+ (plots on the right) 
cells. Data shown are representative of 3 independent experiments. (C) FACS-sorted CD4+ T cells (2 × 105) were cultured for 24 hours in the 
presence or absence of anti-CD3 and anti-CD28, after which IL-17A secretion was measured by flow cytomix assay. Error bars represent 
mean ± SD. n.d., not detectable. (D) Clinical scores after MOG35–55-induced EAE are not significantly altered by increased IL-17A expression 
in CD4-IL17Aind/+ and IL-17Aind/+ littermates. Error bars represent mean ± SEM. Data shown represent 1 out of 3 independent experiments. 
(E) Lymphocytes isolated from the diseased EAE brain and spinal cord at day 14 from CD4-IL17Aind/+ and IL-17Aind/+ littermates were restimu-
lated and surface stained for CD4 and examined for EGFP expression. Further staining for IL-17A and IFN-γ was performed. Percentages of 
EGFP+IL-17A+ or EGFP+IFN-γ+ are given in the quadrant corners. Plots shown are gated on CD4+ CNS-derived T cells. (F) At peak disease, 
mononuclear infiltrates were isolated from inflamed CNS extracts from either CD4-IL17Aind/+ or IL-17Aind/+ mice. Cellular extracts were cultured 
for 2 days in the presence of 20 μg/ml MOG peptide, after which cytokine secretions were measured by flow cytomix. Error bars represent 
mean ± SD and significance is shown where relevant. *P = 0.039, Student’s t test.
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Detailed clinical development of EAE in IL-17A–overexpressing, 
IL-17A–, and IL-17F−deficient mice
	 Day	of		 Incidence	 Maximum		
	 onsetA	 	 scoreA
CD4-IL17Aind/+ 10 ± 0.5 93% (13/14) 2.91 ± 0.29
IL-17Aind/+ 10 ± 0.3 92% (12/13) 2.67 ± 0.13
Il17a−/− 10 ± 0.3 91% (32/35) 2.36 ± 0.13
Il17a+/+ 9 ± 0.4 100% (46/46) 2.75 ± 0.19
Il17f−/− 11 ± 0.3 95% (37/39) 2.68 ± 0.10
Il17f+/− 10 ± 0.3 90% (38/42) 2.74 ± 0.12
Il17f+/+ 12 ± 0.7 100% (17/17) 2.67 ± 0.15
Il17f−/− + αIL-17A 15 ± 0.8 75% (9/12) 2.47 ± 0.29
Il17f−/− + Iso. ctrl. 13 ± 0.5 83% (10/12) 2.70 ± 0.19
AMean of diseased mice (Mean ± SEM). Iso. ctrl., isotype control.
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Systemic overexpression of IL-17A in Del-IL17Aind/+ 
leads to granulocytosis and anemia. (A) Crossing the 
IL-17Aind allele to the delete-cre strain yields mice 
called Del-IL17Aind/+. Skin inflammation, stunted growth, 
and failure to thrive is a consistent phenotype in all mice 
observed when compared with delete-cre littermate 
controls (Del). (B) Single-cell suspensions from bone 
marrow, spleen (SPL), thymus (THY), and mesenteric 
LNs (mLN) were placed in unstimulated culture for 24 
hours, after which IL-17A secretion was assayed by 
ELISA. Error bars represent mean ± SEM. (C) Bone 
marrow cells were isolated from Del-IL17Aind/+ mice 
and littermate controls and surface stained for Gr1 and 
CD11b. Percentages of gated granulocytes are shown 
in quadrant corners. (D) Isolated spleen cells and 
PBMCs from the indicated genotypes were stained for 
MHC-class II and Gr1. Percentages of gated cells are 
shown. (A–D) Data shown are representative of at least 
2 independent experiments.
Table 
Chemical analysis of the blood compartment
Blood	 Del-IL17Aind/+	A	 DelB
wbc (×103 cells/μl) 4.20 1.77 1.35 1.53 1.50 3.63
rbc (×106 cells/μl) 6.18 5.34 3.45 4.36 8.74 7.98
Hemoglobin (g/dl)C 9.00 7.80 8.00 14.20 14.60 12.60
Hematocrit (%)D 31.20 27.30 29.50 46.00 47.20 44.80
Mean corpuscular volume (fl)E 50.40 50.90 46.10 53.90 54.00 56.00
Mean corpuscular hemoglobin (pg)F 14.50 14.60 12.50 16.20 16.70 15.70
Mean corpuscular hemoglobin concentration (g/dl) 28.70 28.70 27.00 30.00 30.90 28.00
AIL-17Aind/+ mice crossed with the deleter-cre strain. Bdeleter-cre control littermates. CP = 0.0015. DP = 0.0002. E P = 0.0301. FP = 0.0347. Routine CBC 
analysis was performed on blood samples from the indicated mice (n = 3). Each column represents an individual mouse. Significant alterations in values 
are shown. Data shown are representative of at least 2 independent experiments.
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IL-17A is redundant in the induction of EAE, which could be due to a 
compensatory increase of IL-17F production. (A) EAE was induced 
in Il17a−/− and Il17a+/+ mice by immunization with MOG35–55/CFA. The 
graph shows the development of EAE according to clinical scores 
(n = 10; SEM as indicated) in 1 out of 2 independent experiments. 
(B and C) Th17-cytokine profile measured by ELISA of splenocytes 
isolated from mice with active EAE and restimulated with MOG35–55 
with (C) or without (B) the addition of Th17 polarizing conditions for 
2 days. Error bars represent mean ± SEM. (D) Comparative mRNA 
expression analysis of Il17f and Il17a in the cerebellum of mice at 
peak EAE versus healthy controls (HC). The data represent 1 of 2 
independent experiments (n = 4). (E) Th17 cells were generated in 
vitro from MOG35–55-immunized C57BL/6 mice. Splenocytes were har-
vested 7 days after immunization, Th17 polarized, and analyzed by 
intracellular cytokine staining for IL-17A, IL-17F, and IFN-γ. Percent-
ages of gated cells are shown. A representative of 3 independent 
experiments is shown.
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IL-17F is not required for the development of EAE. (A) EAE was induced in Il17f−/−, Il17f−/+, and Il17f+/+ mice by immunization with MOG35–55/CFA. 
The graph shows the development of EAE according to clinical scores in 1 out of 5 independent experiments. Error bars represent mean ± SEM. 
(B) Spinal cord cross sections, in accordance with clinical EAE scores, displayed similar inflammatory lesions (H&E staining; arrows). Inflamma-
tion caused an impairment of myelinated structures (staining for CNPase) and induced a reactive astrogliosis (staining for glial fibrillary acidic 
protein [GFAP]). All stainings were performed on serial sections. Scale bars: 500 μm (first column); 50 μm (second, third, and fourth columns). 
Rectangle in first column represents the area shown in second, third, and fourth columns. (C) Detailed analysis of infiltrating lymphocytes into 
cerebellum and spinal cord was performed by cytofluorometric analysis of surface marker staining. CD45high cells represent the CNS-invading 
leukocytes, which were gated on for detailed analysis. Error bars represent mean ± SEM.
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Loss of IL-17F does not impact on T cell priming and does not lead to 
compensatory upregulation of IL-17A. (A–C) Mice were immunized 
with MOG35–55/CFA and lymphocytes were isolated from LNs prior to 
disease onset at 7 days after immunization. Cells were rechallenged 
with 50 μg/ml of MOG35–55, and IL-17A and IL-2 were measured by 
ELISA (A) and ELISPOT (B). (C) Proliferation of effector Th cells upon 
stimulation with MOG35–55 peptide or concanavalin A (ConA) was mea-
sured by thymidine incorporation. (A–C) A representative of 3 inde-
pendent experiments is shown. Error bars indicate SEM of measured 
replicates. (D) Splenocytes from naive mice were polarized toward the 
Th17 effector type in vitro, and IL-17A, IL-17F, and IFN-γ were mea-
sured by intracellular cytokine staining. Dot plots are gated on Th cells 
(CD4+), and histograms are gated on Th17 cells (CD4+, IL-17A+). (E) 
Within the IL-17A–expressing Th17 compartment, IL-17F production is 
shown for each genotype. (F) CNS-infiltrating lymphocytes were isolat-
ed on day 24, after immunization from severely sick mice, restimulated 
with PMA/ionomycin and Brefeldin A for 5 hours, and analyzed for their 
IL-17A and IFN-γ expression by flow cytometry. (D–F) Percentages of 
gated cells are shown. 
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Loss of IL-17F and inhibition of IL-17A does not significantly impact on 
the development of EAE. EAE was induced in IL-17F−deficient mice by 
immunization with MOG35–55/CFA. To antagonize IL-17A function, 200 
μg of neutralizing anti–IL-17A mAb or the respective isotype control 
mAb was injected i.p. every fourth day, starting on day 4 after immuni-
zation. The graph shows the development of EAE according to clinical 
scores in 1 out of 2 independent experiments. Error bars represent 
mean ± SEM. Iso. ctrl., isotype control.
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